VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation

被引:204
作者
Geisen, C
Watzka, M
Sittinger, K
Steffens, M
Daugela, L
Seifried, E
Müller, CR
Wienker, TF
Oldenburg, J
机构
[1] Univ Clin Bonn, Inst Expt Haematol & Transfus Med, D-53127 Bonn, Germany
[2] Inst Transfus Med & Immunohaematol, Dept Mol Haemostasis, DRK Blood Donor Serv Baden Wuerttemberg Hessen, Frankfurt, Germany
[3] Univ Bonn, Inst Med Biometry Informat & Epidmemiol, D-5300 Bonn, Germany
[4] Univ Wurzburg, Inst Human Genet, Bioctr, Wurzburg, Germany
关键词
vitamin K epoxide reductase; VKORC1; warfarin; vitamin K; haplotype;
D O I
10.1160/TH05-04-0290
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In order to elucidate the role of VCORC1 sequence variants in warfarin sensitivity, we established a complete SNP map of the VKORC1 gene locus in 200 blood donors from Western Germany. Nearly all of the genetic variability of the VKORC1 gene in Europeans is reflected by three main haplotypes. Recently described polymorphisms associated with low warfarin dose requirement (dbSNP:rs9934438; dbSNP:rs17878363) were found in complete linkage disequilibrium with the VKORC1*2 haplotype. In two patient cohorts of European origin with either increased coumarin sensitivity (n = 14) or partial coumarin resistance (n=36) the VKORC1*2 frequency varied highly significant between the two groups and also when compared to 200 blood donor controls (coumarin sensitive 96%, coumarin resistant 7%, controls 42%) thus demonstrating a strong association between these two phenotypes and the VKORC1 haplotype (p = 1.6 x 10-(8) for coumarin sensitive and p = 1.9 x 10(-8) for coumarin resistant). Analysis of database derived VKORC1 genotypes of African Americans and Chinese revealed that haplotype frequencies in these populations differ significantly from the European sample (for VKORC1*2: Europeans 42%, Chinese 95%, African Americans 14%). These observations suggest VKORC1 as principal genetic modulator of the ethnic differences in warfarin response. Since hereditary pharmacodynamic (VKORC1) and pharmacokinetic (CYP2C9) factors account for up to 50% of the inter-individual variability of the warfarin response, these genetic markers may serve as clinically relevant predictors of warfarin dosing in future studies.
引用
收藏
页码:773 / 779
页数:7
相关论文
共 38 条
[1]   Patient-specific factors predictive of warfarin dosage requirements [J].
Absher, RK ;
Moore, ME ;
Parker, MH .
ANNALS OF PHARMACOTHERAPY, 2002, 36 (10) :1512-1517
[2]   Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications [J].
Aithal, GP ;
Day, CP ;
Kesteven, PJL ;
Daly, AK .
LANCET, 1999, 353 (9154) :717-719
[3]   A powerful strategy to account for multiple testing in the context of haplotype analysis [J].
Becker, T ;
Knapp, M .
AMERICAN JOURNAL OF HUMAN GENETICS, 2004, 75 (04) :561-570
[4]   The physiology of vitamin K nutriture and vitamin K-dependent protein function in atherosclerosis [J].
Berkner, KL ;
Runge, KW .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (12) :2118-2132
[5]   Cytochrome P4502C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity [J].
Bodin, L ;
Verstuyft, C ;
Tregouet, DA ;
Robert, A ;
Dubert, L ;
Funck-Brentano, C ;
Jaillon, P ;
Beaune, P ;
Laurent-Puig, P ;
Becquemont, L ;
Loriot, MA .
BLOOD, 2005, 106 (01) :135-140
[6]   The association of vitamin K status with warfarin sensitivity at the onset of treatment [J].
Cushman, M ;
Booth, SL ;
Possidente, CJ ;
Davidson, KW ;
Sadowski, JA ;
Bovill, EG .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 112 (03) :572-577
[7]   A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin [J].
D'Andrea, G ;
D'Ambrosio, RL ;
Di Perna, P ;
Chetta, M ;
Santacroce, R ;
Brancaccio, V ;
Grandone, E ;
Margaglione, M .
BLOOD, 2005, 105 (02) :645-649
[8]  
Daly Ann K, 2003, Semin Vasc Med, V3, P231
[9]   A COMPARISON OF LINKAGE DISEQUILIBRIUM MEASURES FOR FINE-SCALE MAPPING [J].
DEVLIN, B ;
RISCH, N .
GENOMICS, 1995, 29 (02) :311-322
[10]   A FLEXIBLE LOADING DOSE SCHEDULE FOR WARFARIN THERAPY [J].
FERGUSSON, RJ ;
EADE, OE ;
LOGIE, AW ;
GADDIE, J .
SCOTTISH MEDICAL JOURNAL, 1987, 32 (06) :169-171